- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39 result(s) found for: Pulmonary surfactant.
Displaying page 1 of 2.
EudraCT Number: 2020-001886-35 | Sponsor Protocol Number: RHMCRI0399 | Start Date*: 2020-05-15 | |||||||||||
Sponsor Name:University Hospital Southampton NHS Foundation Trust | |||||||||||||
Full Title: A clinical trial of nebulized surfactant for the Treatment of moderate to severe COVID-19 in adults | |||||||||||||
Medical condition: COVID-19 infection in patients requiring endotrachael intubation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003106-72 | Sponsor Protocol Number: IIBSP-SUR-2022-61 | Start Date*: 2023-05-26 |
Sponsor Name:Institut de Recerca H. de la Santa Creu i Sant Pau | ||
Full Title: Single-blind randomized clinical trial in premature infants with Respiratory Distress Syndrome (RDS) amenable to treatment with exogenous surfactant identified early by pulmonary ultrasonography | ||
Medical condition: Respiratory Distress Syndrome | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001169-18 | Sponsor Protocol Number: UoL001360 | Start Date*: 2018-10-15 | ||||||||||||||||
Sponsor Name:University Of Liverpool | ||||||||||||||||||
Full Title: The efficacy and mechanism of surfactant therapy for critically ill infants with bronchiolitis: The Bronchiolitis Endotracheal Surfactant Study. | ||||||||||||||||||
Medical condition: Critical Illness due to Bronchiolitis of infancy requiring conventional invasive Mechanical Ventilation (MV) Diagnosis of bronchiolitis per clinical criteria defined in national guidance NICE-NG9. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003224-31 | Sponsor Protocol Number: 557087CE | Start Date*: 2008-03-10 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA | |||||||||||||
Full Title: EFFECT OF SURFACTANT IN the CINETIC AND INFLAMMATION IN the NEW-BORN PRETERM WHIT RDS SINDROM. | |||||||||||||
Medical condition: PREMATURY NEWBORN WITH WEIGTH = OR < TO 1250g IN ARTIFICIAL VENTILATION | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005429-21 | Sponsor Protocol Number: OPTIMIST-Aprotocol | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Menzies Research Institute Tasmania | |||||||||||||
Full Title: Multicentre randomised controlled trial of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation on continuous positive airway pressure (CPAP) | |||||||||||||
Medical condition: Infant respiratory distress syndrome, also known as hyaline membrane disease. | |||||||||||||
|
|||||||||||||
Population Age: In utero, Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA SI (Completed) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003764-45 | Sponsor Protocol Number: UOL0727 | Start Date*: 2020-02-14 |
Sponsor Name:University of Leicester | ||
Full Title: Multicentre, open-label, randomised controlled trial of early surfactant therapy versus expectant management in late preterm and early term infants with respiratory distress. | ||
Medical condition: Respiratory distress in neonates born at 34 to 38+6 weeks of gestation | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004198-41 | Sponsor Protocol Number: UCDCRC/16/003 | Start Date*: 2017-01-27 | |||||||||||
Sponsor Name:University College Dublin | |||||||||||||
Full Title: PROPHYLACTIC OROPHARYNGEAL SURFACTANT FOR PRETERM INFANTS: A RANDOMISED TRIAL (THE POPART TRIAL) | |||||||||||||
Medical condition: Preterm Infants at risk of respiratory distress syndrome | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) BE (Completed) SE (Completed) CZ (Completed) PT (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002923-13 | Sponsor Protocol Number: 2535 | Start Date*: 2021-04-15 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA OSPEDALI RIUNITI DI ANCONA | |||||||||||||
Full Title: Indication for the exougenous surfactant administration to treat neonatal respiratory distress syndrome in the preterm infant: a single-center randomized phase 4 trial based on the comparison of tw... | |||||||||||||
Medical condition: Neonatal respiratory distress syndrome (RDS) | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000489-37 | Sponsor Protocol Number: SURF-04-01 | Start Date*: 2005-08-26 |
Sponsor Name:Nektar Therapeutics | ||
Full Title: An open label, randomized, controlled study to evaluate the safety and efficacy of aerosolized surfactant, Curosurf®, delivered via nasal continuous positive airway pressure pulmonary drug delivery... | ||
Medical condition: The medical condition for this application is the Respiratory Distress Syndrome (RDS). RDS, also known as hyaline membrane disease, is characterized by lung immaturity and surfactant deficiency a... | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-002550-30 | Sponsor Protocol Number: DM/PR/5000/003/05 | Start Date*: 2006-11-09 |
Sponsor Name:Chiesi Farmaceutici S. p. A. | ||
Full Title: A randomized controlled pilot study for the comparison of efficacy of bronchoalveolar lavage (BAL) with Curosurf® in a dosage 50 mg/kg vs not treated control in adult patients affected by pulmonary... | ||
Medical condition: lung contusion | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-000896-30 | Sponsor Protocol Number: Uni-Koeln-439 | Start Date*: 2009-02-09 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: Surfactant application during spontaneous breathing with CPAP or during mechanical ventilation in the therapy of IRDS in premature infants <27 weeks | |||||||||||||
Medical condition: Idiopathic Respiratory Distress Syndrome (IRDS) in preterm infants | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003878-33 | Sponsor Protocol Number: MOL-PAP-002 | Start Date*: 2016-01-28 | |||||||||||
Sponsor Name:Savara ApS | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients | |||||||||||||
Medical condition: Autoimmune Pulmonary Alveolar Proteinosis (aPAP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DK (Completed) NL (Completed) DE (Completed) GR (Completed) ES (Completed) IT (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002258-60 | Sponsor Protocol Number: UMCN-ONCO-201302 | Start Date*: 2013-08-30 | |||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | |||||||||||||
Full Title: prediction of everolimus-induced interstitial lung disease in breast cancer patients; maximizing efficacy by reducing toxicity | |||||||||||||
Medical condition: breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003181-12 | Sponsor Protocol Number: HOTPOT1 | Start Date*: 2016-10-07 |
Sponsor Name:Royal College of Surgeons in Ireland | ||
Full Title: Can sonographic assessment of pulmonary vascular reactivity following maternal hyperoxygenation therapy predict neonatal outcome in fetuses at risk of pulmonary hypertension? | ||
Medical condition: Persistent pulmonary hypertension of the newborn (PPHN) is a relatively common condition occurring in 7/1000 births and can result in significant cardiovascular instability in the newborn. It occur... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001331-22 | Sponsor Protocol Number: CCD-1011-PR-0059 | Start Date*: 2012-05-07 | ||||||||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | ||||||||||||||||||
Full Title: A FIRST IN HUMAN CLINICAL STUDY ON THE SAFETY AND TOLERABILITY OF TWO ESCALATING SINGLE DOSES OF CHF 5633 (SYNTHETIC SURFACTANT) IN PRETERM NEONATES WITH RESPIRATORY DISTRESS SYNDROME | ||||||||||||||||||
Medical condition: preterm neonates with Respiratory Distress Syndrome (RDS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) CZ (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-004105-25 | Sponsor Protocol Number: DM/PR/5000/002/04 | Start Date*: 2007-02-12 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S p A | |||||||||||||
Full Title: AN INTERNATIONAL, OPEN, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE EFFICACY OF COMBINING PROPHYLACTIC CUROSURF WITH EARLY NASAL CPAP VERSUS EARLY NASAL CPAP ALONE IN VERY PRETERM INFANTS AT RISK ... | |||||||||||||
Medical condition: Neonatal Respiratory Distress Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) IT (Completed) FR (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003233-14 | Sponsor Protocol Number: 18CH129 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:CHU de Saint Etienne | |||||||||||||||||||||||
Full Title: Evaluation of the neonatal autonomic stress during intubations under Propofol in a population of premature infants under 33 w’GA | |||||||||||||||||||||||
Medical condition: population of premature infants under 33 w’GA requiring intubation for the administration of exogenous surfactant | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005125-12 | Sponsor Protocol Number: LIRALUNG | Start Date*: 2016-05-12 |
Sponsor Name:Dr. Albert Lecube, Ph.D., M.D. | ||
Full Title: MULTICENTRE RANDOMIZED DOUBLE BLIND, CROSSOVER, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFECT OF LIRAGLUTIDE ON LUNG FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (LIRALUNG STUDY) | ||
Medical condition: Type 2 Diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003519-40 | Sponsor Protocol Number: 03-CL-1202 | Start Date*: 2016-02-18 | |||||||||||||||||||||
Sponsor Name:Windtree Therapeutics, Inc | |||||||||||||||||||||||
Full Title: A MULTINATIONAL, MULTICENTER, MASKED, RANDOMIZED, CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF LUCINACTANT FOR INHALATION IN PRETERM NEONATES 26 TO 32 WEEKS GESTATIONAL AGE WITH RESPIRATOR... | |||||||||||||||||||||||
Medical condition: Respiratory Distress Syndrome (RDS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Completed) IE (Completed) NL (Completed) HU (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000106-32 | Sponsor Protocol Number: 03-CL-1702 | Start Date*: 2019-06-26 | |||||||||||||||||||||
Sponsor Name:Windtree Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: A Multinational, Multicenter, Masked, Randomized, Parallel Group, Controlled Study to Assess the Safety and Efficacy of Lucinactant for Inhalation versus nCPAP alone in Preterm Neonates 26 to 32 We... | |||||||||||||||||||||||
Medical condition: Respiratory Distress Syndrome (RDS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
